

Fecal microbiota transplantation: lights and shadows of a new weapon against inflammatory bowel disease

Andrea Piccioni¹, Federico Rosa², Federica Manca², Davide Antonio Della Polla¹, Martina Petrucci¹, Benedetta Simeoni¹, Marcello Covino^{1,2}

¹ Department of Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

² Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy

Corresponding Author: Andrea Piccioni, MD; e-mail: andrea.piccioni@policlinicogemelli.it

ABSTRACT

Treatment of inflammatory bowel disease (IBD) remains one of the most critical public health issues, mostly due to its wide global prevalence and dramatic impact on patients' quality of life.

One of the many mechanisms implicated in the pathogenesis of this disease appears to be attributable to gut microbiota dysbiosis. For this reason, similar to what happened for *Clostridium difficile*, fecal microbiota transplantation is making its way as a possible new therapeutic weapon in the treatment of this disease.

In this article, we will discuss the strengths of this promising treatment, while also discussing the controversial aspects and concerns regarding one of the most innovative therapies of recent times.

INTRODUCTION

In recent years, the gut microbiota has received considerable interest. Many studies have shown that gut microbiota plays a role in the pathogenesis of several chronic health conditions.

Gut microbiota's modification in composition and function causes significant dysfunction of intestinal permeability, digestion and metabolism, and it promotes immune response and pro-inflammatory state. This can trigger many diseases ranging from gastrointestinal and/or metabolic conditions to immunological and neuropsychiatric diseases¹.

Gut microbiota composition

Microbiota is composed of ten trillion diverse symbionts, 50 bacterial phyla, and about 100-1000 bacterial species colonizing the human gut. The cumulative genes of microbiota are known as the 'microbiome', which is 150 times larger than the human genome^{2,3}.

The human gut microbiota consists of several types of microbes, including bacteria, archaea, eukarya, viruses, and parasites. Among bacteria, there are seven predominant divisions: *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, *Fusobacteria*, *Proteobacteria*, *Verrucomicrobia*, and *Cyanobacteria*².

More than 90% of the total population is composed of *Bacteroidetes* and *Firmicutes*. Under the phylum *Bacteroidetes*, most of the microbes belong to the genera of *Bacteroides* and *Prevotella*, and under the phylum *Firmicutes* *Clostridium*, *Eubacterium* and *Ruminococcus* are predominant⁴.

KEYWORDS

GUT MICROBIOTA

INFLAMMATORY BOWEL DISEASE

FECAL MICROBIOTA

TRANSPLANTATION

ULCERATIVE COLITIS

CROHN'S DISEASE

MICROBIOME

Each gastrointestinal tract harbors distinct bacterial communities that vary in density and diversity because of the distinct gastrointestinal regions concerning different microenvironments due to its anatomical and functional characteristics, which can be the cause of selecting growth of specific microbiota⁵.

The gastrointestinal microbiota composition may be affected by some environmental parameters, such as pH, oxygen levels/redox state, availability of nutrients, water activity, and temperature⁶.

In the stomach, more than 65% of phylotypes originated from the mouth, bacteria such as *Veillonella*, *Lactobacillus*, and *Clostridium*. They were found to be acid-resistant^{7,8}.

The low pH of the gastric lumen limits the type of microbes that can live in that environment, selecting for acid-resistant bacterial populations. Previously, the stomach was thought to be sterile because of the bactericidal barrier, reflux of bile acids, the thickness of the mucus layer, and gastric peristalsis. In 1981, The Lancet reported a large number of acid-resistant bacteria in the stomach, such as *Streptococcus*, *Neisseria*, and *Lactobacillus*.

One year later, '*Campylobacter pyloridis*' was discovered by Robin Warren and Barry Marshall, and later, it was named *Helicobacter pylori* (*H. pylori*). The presence of *H. pylori* affects the rest of the gastric microbiome, which can be a simple commensal species or a pathogen⁹.

Blaser et al¹⁰ were the first to propose the eradication in several gastric diseases.

The small intestine tract is characterized by a rapid luminal flow, secretion of bactericidal substances (e.g., bile acids), and plenty of oxygen. All these characteristics can limit bacterial diversity and density^{11,12}.

Firmicutes and *Actinobacteria* are the predominant phyla in the duodenum. The jejunum supports the growth of Gram-positive aerobes and facultative anaerobes (10^3 - 7 CFU/ml), including *Lactobacilli*, *Enterococci*, and *Streptococci*. In the transition to the ileum, the bacterial density reaches up to 10^9 CFU/ml with a predominance of aerobic species. In contrast, the distal part of the ileum close to the ileocecal valve is populated with anaerobes and Gram-negative organisms similar to the colon¹³.

In the large intestine, the bacterial density reaches 10^{12} CFU/ml and is dominated by *Firmicutes* and *Bacteroidetes*. The large intestine is a predominant site of water absorption and fermentation of undigested food, also characterized by the slower transit of food and its anaerobic condition. So, the predominant species are anaerobes.

The colonic microbiota contributes to the digestion of undigested dietary ingredients, and the microbiota's metabolites are subsequently available for absorption by the colonic mucosa.

In terms of bacterial composition, the dominant microbes are *Bacteroides*, *Bifidobacterium*, *Streptococcus*, *Enterobacteriaceae*, *Enterococcus*, *Clostridium*, *Lactobacillus*, and *Ruminococcus*⁸.

Plus, there are two types of microbes composing gut microbiota: the autochthonous, also known as indigenous, and the allochthonous or transient microorganisms.

In this context, only a relatively small number of opportunistic pathogens are considered to be members of the gut microbiota, residing unperturbed within the enteric host microbiota and becoming a health threat to the host only when the gut ecosystem is disturbed, and the gut microbiota homeostasis becomes disrupted^{14,15}.

Recent developments in technologies about genome sequencing, and bioinformatics enables researchers to explore the microbiota and its functions at a more detailed level than ever before. Evidence suggests that a part of the microbiota is conserved, and the other one is a dynamic microbiota. As well as its variation in different gastrointestinal tracts, it can vary from infants to elderly, primitives to modern human beings, and modify its composition in different health conditions.

From infants to elderly

The shaping and multiplication of gut microbiome start at birth, while the modification of their composition depends mainly on various genetic, nutritional, and environmental factors.

The development of gut microbiota in infants constitutes a dynamic process, in which positive and negative interactions occur.

This process is influenced by various perinatal conditions, such as mode of delivery, diet, mother's age, metabolic status, type of feeding, lifestyle, and antibiotic use. These factors have been reported to impact the infant microbiota^{16,17}.

Overview of inflammatory bowel disease

Inflammatory bowel disease (IBD) is one of the major public health problems worldwide because of its increasing prevalence and the severe consequences on the lives of affected patients.

IBD mainly comprise two entities, ulcerative colitis (CU) and Crohn's disease (CD).

While ulcerative colitis affects the colon, Crohn's disease can affect any area of the gastrointestinal tract, from the mouth to the perianal area¹⁸.

Very often, inflammatory bowel disease does not have

a predictable, linear course and can be considered a chronic, relapsing, and remitting disease¹⁹.

The prevalence of IBD worldwide has been steadily increasing and has seen its incidence nearly double in less than 30 years, from 3.7 million cases in 1993 to 6.8 million in 2017²⁰.

Pathogenesis of IBD appears to be multifactorial in origin, and as in many other autoimmune diseases, environmental mechanisms seem to be involved over a genetic predisposition²¹. The mechanisms involved in the pathogenesis seem to be really multiple, and in addition to those already mentioned common to many autoimmune diseases, there are some peculiar to the gastrointestinal tract, such as a dysfunction of the mucosal barrier, alterations in the microbiota, a dysregulation of the immune system, and lifestyle²². Characteristic symptoms are abdominal pain, bloody diarrhea, and tenesmus, with significant effects on the patient's quality of life²³.

Ulcerative colitis is associated with other notable complications, such as the risk of colectomy²⁴, and an increased risk of developing colorectal cancer compared to the general population²⁵.

IBD can occur at any age, although the peak incidence has been found in the population between the ages of 15 and 30 years, although according to some authors, there is a second peak between the ages of 50 and 80 years²⁶. Despite the many similarities between the two forms of inflammatory bowel disease, several aspects differentiate them.

Ulcerative colitis predominantly affects the male sex, while Crohn's disease affects the female, which is why hormonal mechanisms have also been hypothesized to be behind its pathogenesis²⁷.

Regarding environmental risk factors, the best-known difference between the two forms is exposure to cigarette smoke, which, as is well known, increases the risk of developing Crohn's disease, but is not associated with the onset of ulcerative colitis²⁸.

Regarding treatment, as both of these conditions are sustained by an autoimmune-type inflammatory mechanism, their therapy finds its cornerstone in the use of aminosalicylates (Sulfasalazine) and other types of 5-aminosalicylic acid (5-ASA) drugs, immunomodulators such as thiopurines (TPs), methotrexate (MTX), calcineurin inhibitors, and Janus Kinase (JAK) inhibitors, corticosteroids, and biologic drugs such as pro-inflammatory cytokine inhibitors and integrin antagonists²⁹.

Precisely because most currently approved therapies are immunosuppressive and linked to major side effects in the long run, new therapeutic strategies have been tried, for example, by going for microbiota manipulation.

The relationship between gut microbiota and IBD

In recent years, studies dedicated an important role of gut microbiota changes in the onset of IBD.

The gut microbiota seems to be the most important environmental factor involved in the development of inflammatory bowel disease³⁰. Nevertheless, for some authors, the role of the microbiome in gut inflammation is still controversial as it could be considered either the cause or the consequence, or even both³¹.

Differences in the composition of the gut microbiota in patients with IBD

According to some authors, in patients with Crohn's disease, the phylum *Firmicutes* seems to decrease, while that of *Proteobacteria*, such as *Enterobacteriaceae* and *Escherichia coli*, increases (Figure 1)³².

In patients with Crohn's disease also, an increase in mucosal bacterial counts and a concomitant decrease in *Faecalibacterium prausnitzii*, a commensal microorganism with anti-inflammatory activity, was found³³.

Reduced levels of *Bacteroidetes* and a consistent decrease in microbial richness were also found in patients with active inflammation³⁴.

An intriguing theory starts from the assumption that inflammatory bowel disease is recognized as a disease with autoimmune genesis, and according to some authors, this exaggerated immune response may be toward the commensal microbiota, although no specific microorganism has been identified²¹.

Knowledge of the gut microbiota for the development of new therapeutic strategies

As mentioned above, in inflammatory bowel disease, there seems to be dysbiosis with a decrease in *Firmicutes* such as *Bifidobacteria*, *Lactobacilli*, and *Faecalibacterium prausnitzii*³⁵.

Precisely, because *Firmicutes* are the microorganisms most involved in the production of short-chain fatty acids such as butyrate, a substrate with immunoregulatory properties, butyrate enemas have been attempted as a therapeutic weapon³⁶.

A fascinating avenue for manipulating the microbiota has been attempted through the use of prebiotics, probiotics, paraprobiotics, postbiotics, and synbiotics³⁷.

With prebiotics, an attempt is made to modify the microbiota through the diet, while with probiotics, beneficial bacteria are directly supplemented with the diet. The products that combine these two therapies are symbiotics instead.

Paraprobiotics are defined as non-viable, inactivated bacteria or their components, while postbiotics are products of bacterial metabolism or equal synthetic

products modulating the inflammatory and immune response³⁷.

This is also a promising field of study that deserves separate discussion because of its vastness.

The topic we will discuss, fecal microbiota transplantation, conceptually takes up the same idea as these treatments, with a quite different approach.

Fecal microbiota transplantation (FMT), is a treatment that manipulates the microbiota, now well established in the treatment of recurrent *Clostridium difficile* infection.


As we will see below, FMT represents one of the latest hot discussion topics regarding the increasingly well-known relationship between inflammatory bowel disease and microbiota³⁸.

is a valid option⁴⁰, since it restores the balance of normal microbial flora, unlike antibiotic treatments, which can aggravate the intestinal dysbiosis that leads to the onset of *C. difficile* overgrowth⁴¹.

We have previously seen how dysbiosis also underlies the onset of inflammatory bowel disease.

The first evidence of the use of FMT for the treatment of IBD was described in patients treated for the onset of *Clostridium difficile* overgrowth. In those patients, FMT emerged as a safe and effective treatment⁴¹, while in a minority of patients, FMT acted as a trigger causing a flare of disease³⁹. It is unclear yet why FMT may improve IBD activity in some patients and causes inflammation in others⁴².

Figure 1. Main alterations in the gut microbiota predisposing to the onset of IBD.



The experience of FMT in the treatment of *C. difficile* overgrowth

Therefore, based on the experience with the treatment of *C. difficile* overgrowth, FMT was tested as a possible therapeutic weapon for IBD. Dysbiosis is the condition underlying the onset of *C. difficile* overgrowth.

C. difficile is a gram-positive spore-forming bacillus present in 2-4% of healthy individuals³⁹; this bacterium, harmless to many people, becomes responsible for such a severe infection when a dysbiosis in the microbiota comes to occur.

It is mainly the use of antibiotics that is the trigger that goes on to alter that delicate balance between the host and its commensal microbial flora, leading to colonization, uncontrolled growth, and toxin production until *C. difficile* overgrowth develops³⁹.

The treatment of *C. difficile* overgrowth, therefore, involves the use of antibiotics such as fidaxomicin, vancomycin, and metronidazole, but precisely because by now that delicate balance between microorganisms and host has been irreparably compromised, the risk of recurrence is extremely high. In this case, FMT

FMT

With FMT, we transplant healthy microbiota into patients with unhealthy gut microbiota composition; in this way, we reconstitute its normal physiological functions to treat the underlying disease. In other words, by using FMT, we reverse dysbiosis in the recipient's gut by providing the full spectrum of microorganisms belonging to the healthy donor.

We have already explained how FMT has become one of the approved pivotal therapies for the treatment of recurrent *C. difficile* overgrowth. However, despite its proven efficacy, FMT is often underutilized due to some difficulties, such as donor recruitment, route of administration, and stool handling⁴³.

According to a meta-analysis⁴⁴, the most effective way of administration appears to be through the lower gastrointestinal tract.

Combining FMT with the use of antibiotics has also been tried to increase its efficacy. Patients pretreated with antibiotics before FMT presented a higher clinical remission rate⁴⁵.

Interestingly, following FMT, increased intestinal microbial diversity was indeed found to mirror that of the donor⁴⁴. On this view, it was noted that the greater the donor's microbial diversity and richness, the greater the success rate following FMT³³.

Regarding microbial composition, by performing analysis of fecal samples pre- and post-procedure, patients recovered after FMT showed higher concentrations of *Eubacterium hallii* and *Roseburia inulinivorans* and increased biosynthesis of short-chain fatty acids and secondary bile acids.

Despite all these encouraging results, some obscure aspects remain to be clarified, such as the long-term efficacy of these therapies, the best route of administration, and a proper donor and recipient selection strategy²⁹.

Main evidence on the use of fecal microbiota transplantation in inflammatory bowel disease

As we can see in Table 1, the main evidence supporting the efficacy of FMT in the treatment of ulcerative colitis comes from very recent evidence, starting with a systematic review in 2012 and the very recent trials conducted since 2015.

Regarding more in-depth features, we defer reading the individual studies.

To summarize the main features, these trials still had a low number of participants (the maximum number was reached in Paramsothy's 85), fecal transplantation was in some cases by nasoduodenal tube, in others by colonoscopy or enema, and in some cases, the feces came from a single donor, while in others from multiple donors. In each case, the endpoint was disease remission.

Thus, it becomes evident that a uniform validated protocol needs to be found for future studies to decrease variability.

Regarding some aspects still to be clarified, there are some concerning donor selection and the mode of stool administration.

Most of the evidence on FMT concerns ulcerative colitis, so we also point out two systematic reviews, both from 2021, published on the use of fecal microbiota transplantation for Crohn's disease, in which its therapeutic potential is confirmed.

Table 1. Timeline of the main evidence on the use of fecal microbiota transplantation in inflammatory bowel disease.

Characteristics of the study	Authors and year
Systematic review on IBD	Anderson et al (2012) ⁴⁶
Randomized Controlled Trial on CU	Moayyed et al (2015) ⁴⁷
Randomized Controlled Trial on CU	Rossen et al (2015) ⁴⁸
Systematic review and meta-analysis on CU	Shi Y et al (2016) ⁴⁹
Randomized Controlled Trial on CU	Paramsothy et al (2017) ⁵⁰
Randomized Controlled Trial on CU	Costello et al (2019) ⁵¹
Systematic review on CD	Fehily et al (2021) ⁵²
Systematic review and meta-analysis on CD	Cheng et al (2021) ⁵³
Systematic review and meta-analysis on CU	Wei et al (2022) ⁵⁴
Systematic review and meta-analysis on CU	Huang et al (2022) ⁵⁵

FINAL CONSIDERATIONS

FMT is now a recognized potential therapeutic weapon for the treatment of IBD, although several aspects remain to be clarified (Table 2).

Table 2. Main topics of debate on the use of fecal microbiota transplantation for the treatment of IBD.

Aspects to clarify
Mode of administration
Donor selection
Pre-treatment with antibiotics
Safety
Treatment duration
Long-term effectiveness

The most credited pathogenetic mechanisms for its success are related to increasing microbial diversity⁵⁶ and rebalancing dysbiosis, thus reducing the well-known pro-inflammatory state.

For all these reasons, we agree with Quraishi's view⁵⁷ about the needing for a more personalized approach based on precision medicine. Interestingly, this has been fully understood by a group of researchers who have looked at predictive biomarkers of donor and recipient response to FMT in patients with ulcerative colitis⁵⁸.

Research is more alive than ever on this topic; in fact, we report a recent study of a small group of patients pretreated with antibiotics who were then given FMT orally, with encouraging results⁵⁹.

Although some authors have recently commented on the ineffectiveness of long-term treatment⁶⁰, there is still no unanimity on this aspect, so further studies are certainly needed.

One aspect that should definitely be taken into consideration is the safety of this procedure. With FMT, the aim is to rebalance the dysbiosis underlying the onset of inflammatory bowel disease, but one of the risks of this procedure is then to transfer pathogenic microorganisms into a patient who is very often taking immunosuppressive therapies, thus facing devastating consequences.

For this reason, the choice of the donor is extremely important, as is the careful selection of the recipient. Regarding the side effects of this procedure, those most commonly encountered were disease flares³⁹. In a recent meta-analysis, the overall risk of worsening IBD was estimated to be 14%. This worsening is associated with fecal administration through the lower gastrointestinal tract, although not all authors agree on this⁶¹.

Concerning mortality, we cite a very recent systematic review looking at adverse events over 20 years⁶².

This work found that most adverse effects occurred within one month after FMT, which is then suggested as a cut-off for short- and long-term complications. Anyway, the mortality rate was extremely low (0.13%), most of which occurred due to aspiration pneumonia. This complication was also associated with patients undergoing upper gastrointestinal FMT, so specific arrangements could be considered to prevent it. National registries are also active about complications, and the most cited are American (AGA) or Chinese (CMTS).

The American Registry collects data from 4,000 patients over a 10-year period, while the Chinese one shows the real-time incidence of adverse events on the website. With these new tools, we can definitely monitor the safety of this procedure.

Regarding dysbiosis associated with the onset of IBD, a decrease in *Bacteroidetes* and a predominance of *Proteobacteria* were found (Figure 2)⁶³.


In addition, some important phyla such as *Firmicutes* and *Bacteroidetes* appear to be reduced in diversity, while an increase in *Veillonellaceae*, *Enterobacteriaceae*, *Pasteurellaceae*, and *Fusobacteriaceae*, and a decrease in *Erysipelotrichales*, *Bacteroidales*, and *Clostridiales* have been correlated with disease activity⁵⁶.

Following the procedure, an increase in IBD-protective bacteria, such as *Faecalibacterium* and *Roseburia*, and a decrease in those correlated with IBD worsening, such as *Enterococcus*, *Lactobacillus*, and *Streptococcus*, as well as groups of *Burkholderiales* and *Erysipelotrichaceae* was found⁶³.

Instead, according to some authors, one of the key aspects of the success of FMT seems to be precisely the recovery of *Bacteroidetes*^{64,65}.

Despite those observations, some limitations still occur about the real role of FMT in IBD. Issues such as long-term efficacy, heterogeneity of current trials, way of administration, and donor selection, are not well recognized. Therefore, it is crucial to restart from those open issues to clarify the therapeutic role of FMT in IBD.

Figure 2. Major changes in the gut microbiota resulting from FMT.



Conflict of Interest

The authors declare that they have no conflict of interest.

REFERENCES

- Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. *Antonie Van Leeuwenhoek*. 2020;113(12):2019-2040. Doi: 10.1007/s10482-020-01474-7.
- Matenchuk BA, Mandhane PJ, Kozyrskyj AL. Sleep, circadian rhythm, and gut microbiota. *Sleep Med Rev*. 2020;53:101340. Doi: 10.1016/j.smrv.2020.101340.
- Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010;464(7285):59-65. Doi: 10.1038/nature08821.
- Adak A, Khan MR. An insight into gut microbiota and its functionalities. *Cell Mol Life Sci* 2019;76:473-493. Doi.org/10.1007/s00018-018-2943-4.
- Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. *Gastroenterology* 2014;146(6):1449-1458. Doi: 10.1053/j.gastro.2014.01.052.
- Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. *J Allergy Clin Immunol* 2012;129:1204-1208. Doi: 10.1016/j.jaci.2012.03.010.
- Nardone G, Compare D. The human gastric microbiota: is it time to rethink the pathogenesis of stomach diseases? *United Eur Gastroenterol J* 2015;3(3):255-260. Doi: 10.1177/2050640614566846.
- Kazor CE, Mitchell PM, Lee AM, Stokes LN, Loesche WJ, Dewhirst FE, Paster BJ. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. *J Clin Microbiol*. 2003;41(2):558-563. Doi: 10.1128/JCM.41.2.558-563.2003.
- Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, Perez-Perez G, Blaser MJ, Relman DA. Molecular analysis of the bacterial microbiota in the human stomach. *Proc Natl Acad Sci U S A*. 2006;103(3):732-7. Doi: 10.1073/pnas.0506655103.

10. Blaser MJ. Hypothesis: the changing relationships of *Helicobacter pylori* and humans: implications for health and disease. *J Infect Dis* 1999;179:1523-1530. Doi: 10.1086/314785.
11. Van den Bogert B, Leimena MM, De Vos WM, Zoetendal EG, Kleerebezem M: Functional intestinal metagenomics. In *Handbook of Molecular Microbial Ecology*. Edited by De Bruin FJ. Wiley-Blackwell, 2011; pp. 170-190.
12. De Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. *Nutr Rev* 2012;70(Suppl. 1):S45-S56. Doi: 10.1111/j.1753-4887.2012.00505.x.
13. El Aidy S, van den Bogert B, Kleerebezem M. The small intestine microbiota, nutritional modulation and relevance for health. *Curr Opin Biotechnol*. 2015;32:14-20. Doi: 10.1016/j.copbio.2014.09.005.
14. Ventura M, Turrone F, Canchaya C, Vaughan EE, O'Toole PW, van Sinderen D. Microbial diversity in the human intestine and novel insights from metagenomics. *Front Biosci (Landmark Ed)*. 2009;14(9):3214-3221. Doi: 10.2741/3445.
15. Milani C, Duranti S, Bottacini F, Casey E, Turrone F, Mahony J, Belzer C, Delgado Palacio S, Arbolea Montes S, Mancabelli L, Lugli GA, Rodriguez JM, Bode L, de Vos W, Gueimonde M, Margolles A, van Sinderen D, Ventura M. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. *Microbiol Mol Biol Rev*. 2017;81(4):e00036-17. Doi: 10.1128/MMBR.00036-17.
16. Avershina E, Lundgård K, Sekelja M, Dotterud C, Storrø O, Øien T, Johnsen R, Rudi K. Transition from infant- to adult-like gut microbiota. *Environ Microbiol*. 2016 Jul;18(7):2226-2236. Doi: 10.1111/1462-2920.13248.
17. Avershina E, Storrø O, Øien T, Johnsen R, Wilson R, Egeland T, Rudi K. Bifidobacterial succession and correlation networks in a large unselected cohort of mothers and their children. *Appl Environ Microbiol*. 2013;79(2):497-507. Doi: 10.1128/AEM.02359-12.
18. Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. *Surg Clin North Am*. 2019;99(6):1051-1062. Doi: 10.1016/j.suc.2019.08.001.
19. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. *Proc Nutr Soc*. 2007;66(3):307-15. Doi: 10.1017/S0029665107005563.
20. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2020;5(1):17-30. Doi: 10.1016/S2468-1253(19)30333-4.
21. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. *Inflamm Bowel Dis*. 2012 May;18(5):968-84. Doi: 10.1002/ibd.21866.
22. Ocansey DKW, Zhang L, Wang Y, Yan Y, Qian H, Zhang X, Xu W, Mao F. Exosome-mediated effects and applications in inflammatory bowel disease. *Biol Rev Camb Philos Soc*. 2020;95(5):1287-1307. Doi: 10.1111/brv.12608.
23. Rao SS, Holdsworth CD, Read NW. Symptoms and stool patterns in patients with ulcerative colitis. *Gut*. 1988;29(3):342-345. Doi: 10.1136/gut.29.3.342.
24. Parragi L, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group. Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. *J Crohns Colitis*. 2018;12(7):811-818. Doi: 10.1093/ecco-jcc/jjy040.
25. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. *Aliment Pharmacol Ther*. 2014;39(7):645-659. Doi: 10.1111/apt.12651.
26. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: a population-based study. *Am J Gastroenterol*. 2006 Jul;101(7):1559-1568. Doi: 10.1111/j.1572-0241.2006.00603.x. Erratum in: *Am J Gastroenterol*. 2006 Aug;101(8):1945. PMID: 16863561.
27. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. *Clin Gastroenterol Hepatol*. 2017 Jun;15(6):857-863. Doi: 10.1016/j.cgh.2016.10.039.
28. Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. *Am J Gastroenterol*. 2012;107(9):1399-1406. Doi: 10.1038/ajg.2012.196.
29. Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. *Front Med (Lausanne)*. 2021;8:765474. Doi: 10.3389/fmed.2021.765474.
30. Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. *J Immunol Res*. 2019;2019:7247238. Doi: 10.1155/2019/7247238.

31. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? *IBD Treatment Targeting the Gut Microbiome*. *Pathogens*. 2019;8(3):126. Doi: 10.3390/pathogens8030126.
32. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? *Nat Rev Gastroenterol Hepatol*. 2017 Oct;14(10):573-584. Doi: 10.1038/nrgastro.2017.88.
33. Melgar S, Shanahan F. Inflammatory bowel disease—from mechanisms to treatment strategies. *Autoimmunity*. 2010;43(7):463-477. Doi: 10.3109/08916931003674709.
34. Aberg M, O'Brien CL, Hold GL. Microbiota and IBD. *Microb Health Dis* 2020;2:e277. Doi: 10.26355/mhd_20206_277.
35. Sartor RB. Microbial influences in inflammatory bowel diseases. *Gastroenterology*. 2008;134(2):577-94. doi: 10.1053/j.gastro.2007.11.059. PMID: 18242222.
36. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, de Bruïne A, Bast A, Venema K, Brummer RJ. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. *Clin Nutr*. 2010;29(6):738-744. Doi: 10.1016/j.clnu.2010.04.002.
37. Martyniak A, Medyńska-Przęczek A, Wędrychowicz A, Skoczeń S, Tomasik PJ. Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. *Biomolecules*. 2021;11(12):1903. Doi: 10.3390/biom11121903.
38. Arras W, Koentgen S, Ceuleers H, Little RD. A year of microbiota and IBD – Highlights and advances *Microb Health Dis* 2022;4(3): e776. Doi: 10.26355/mhd_20229_776.
39. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Clin Gastroenterol Hepatol*. 2013;11(8):1036-1038. Doi: 10.1016/j.cgh.2013.04.045.
40. Juszczuk K, Grudlewska K, Mikucka A, Gospodarek E. Fecal microbiota transplantation - methods of treatment of recurrent *Clostridium difficile* infections and other diseases. *Postepy Hig Med Dosw (Online)*. 2017;71(0):220-226. Doi: 10.5604/01.3001.0010.3807.
41. Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, Sadowsky MJ. Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection. *Clin Gastroenterol Hepatol*. 2016;14(10):1433-1438. Doi: 10.1016/j.cgh.2016.02.018.
42. Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N, Sokol H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, Allegretti JR. Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory *Clostridium difficile* Infection in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2016;22:20402-2409. Doi: 10.1097/MIB.0000000000000908.
43. Cammarota G, Ianiro G. FMT for ulcerative colitis: closer to the turning point. *Nat Rev Gastroenterol Hepatol* 2019;16:266-268. Doi: 10.1038/s41575-019-0131-0.
44. Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, Castaño-Rodríguez N. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *J Crohns Colitis*. 2017;11(10):1180-1199. Doi: 10.1093/ecco-jcc/jjx063.
45. Keshteli AH, Millan B, Madsen KL. Pretreatment with antibiotics may enhance the efficacy of fecal microbiota transplantation in ulcerative colitis: a meta-analysis. *Mucosal Immunol*. 2017;10(2):565-566. Doi: 10.1038/mi.2016.123.
46. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. *Aliment Pharmacol Ther*. 2012;36(6):503-516. Doi: 10.1111/j.1365-2036.2012.05220.x.
47. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*. 2015;149(1):102-109.e6. Doi: 10.1053/j.gastro.2015.04.001.
48. Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflo A, Löwenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D'Haens GR, Ponsioen CY. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. *Gastroenterology*. 2015;149(1):110-118.e4. Doi: 10.1053/j.gastro.2015.03.045.
49. Shi Y, Dong Y, Huang W, Zhu D, Mao H, Su P. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. *PLoS One*. 2016;11(6):e0157259. Doi: 10.1371/journal.pone.0157259.
50. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet*. 2017;389(10075):1218-1228. Doi: 10.1016/S0140-6736(17)30182-4.

51. Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. *JAMA*. 2019;321(2):156-164. Doi: 10.1001/jama.2018.20046.
52. Fehily SR, Basnayake C, Wright EK, Kamm MA. Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. *J Gastroenterol Hepatol*. 2021;36(10):2672-2686. Doi: 10.1111/jgh.15598.
53. Cheng F, Huang Z, Wei W, Li Z. Fecal microbiota transplantation for Crohn's disease: a systematic review and meta-analysis. *Tech Coloproctol*. 2021;25(5):495-504. Doi: 10.1007/s10151-020-02395-3.
54. Wei ZJ, Dong HB, Ren YT, Jiang B. Efficacy and safety of fecal microbiota transplantation for the induction of remission in active ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. *Ann Transl Med*. 2022;10(14):802. Doi: 10.21037/atm-22-3236.
55. Huang T, Xu J, Wang M, Pu K, Li L, Zhang H, Liang Y, Sun W, Wang Y. An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis. *Medicine (Baltimore)*. 2022;101(30):e29790. Doi: 10.1097/MD.00000000000029790.
56. Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss AC. Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. *Inflamm Bowel Dis*. 2016;22(9):2182-2190. Doi: 10.1097/MIB.0000000000000893.
57. Quraishi MN, Iqbal TH, Hart AL. Precision Medicine with FMT for Ulcerative Colitis: Are We There Yet? *J Crohns Colitis*. 2021;15(4):519-520. Doi: 10.1093/ecco-jcc/jjaa190.
58. Rees NP, Shaheen W, Quince C, Tselepis C, Horniblow RD, Sharma N, Beggs AD, Iqbal TH, Quraishi MN. Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis. *EBioMedicine*. 2022;81:104088. Doi: 10.1016/j.ebiom.2022.104088.
59. Crothers JW, Chu ND, Nguyen LTT, Phillips M, Collins C, Fortner K, Del Rio-Guerra R, Lavoie B, Callas P, Velez M, Cohn A, Elliott RJ, Wong WF, Vo E, Wilcox R, Smith M, Kassam Z, Budd R, Alm EJ, Mawe GM, Moses PL. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. *BMC Gastroenterol*. 2021;21(1):281. Doi: 10.1186/s12876-021-01856-9.
60. Haifer C, Saikal A, Paramsothy R, Kaakoush NO, Leong RW, Borody TJ, Kamm MA, Paramsothy S. Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy. *Gut*. 2021;70(11):2210-2211. Doi: 10.1136/gutjnl-2020-323581.
61. Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. *Gut Microbes*. 2017;8(6):574-588. Doi: 10.1080/19490976.2017.1353848.
62. Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. *Aliment Pharmacol Ther*. 2021;53(1):33-42. Doi: 10.1111/apt.16148.
63. Kao D, Hotte N, Gillevet P, Madsen K. Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. *J Clin Gastroenterol*. 2014;48(7):625-8. Doi: 10.1097/MCG.0000000000000131.
64. Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T, Hiramatsu K, Watanabe S. Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. *Inflamm Bowel Dis*. 2017;23(1):116-125. Doi: 10.1097/MIB.0000000000000975.
65. De Albuquerque Terra DA, Vilela EG, Silva ROS, Leão LA, Lima KS, Kuijper EJ, Passos RIFA, Coelho L-GV. Experience of the first Brazilian fecal microbiota transplantation center in treating recurrent *Clostridioides difficile* infection. *Microb Health Dis*. 2022;4:e806. Doi: 10.26355/mhd_202212_806.